Prenosis develops precision medicine tools and implements them in real time for acute care settings, focusing on personalizing healthcare based on individual biology. They leverage their Immunix precision medicine platform and have created the FDA authorized Sepsis ImmunoScore.

Prenosis

AC Immune SA is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. It integrates diagnostic and therapeutic candidates in its pipeline.

AC Immune SA

Almac Group provides services across the drug development lifecycle, including pharmaceutical development, diagnostics, and clinical services. The company supports global pharma and biotech firms with tailored solutions.

Almac Group

Amgen Bangladesh is a subsidiary of Amgen Inc., one of the world's leading biotechnology companies. The company is dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. It focuses on areas of high unmet medical need, leveraging expertise in biology, chemical engineering, and a variety of other scientific disciplines to develop medicines that can help millions of patients around the world.

George Rathmann

Amgen Bangladesh

Prenosis develops precision medicine tools for sepsis diagnosis and prediction using AI technology, offering the ImmunoScore diagnostic platform that integrates with hospital systems.

Prenosis | 2,709 followers on LinkedIn. Transforming clinical diagnosis with predictive intelligence. | Prenosis is transforming clinical diagnosis with artificial intelligence that leverages holistic molecular and clinical data.

Advisor and investor looking to help solve big problems in healthcare.

Gary Kurtzman, MD

Health Tech Investor | Founder | Advisor | Mother

Julia Monfrini Peev

Executive Director Business Development @ Prenosis | Clinical Acumen | Sales Leadership | Real World Evidence

Jim Sianis, B.S., PharmD, MBA

Strategist/Executive/Leader connecting companies with capital | Investing and advising early/mid-stage companies | Supporting entrepreneurs in animal…

Craig S. Wallace

Breaking News! Prenosis — an artificial intelligence company enabling precision medicine in acute care — is proud to announce that the FDA has granted marketing authorization (De Novo pathway) for the Sepsis ImmunoScore™, our AI diagnostic and predictive tool for early detection of sepsis. This signifies the first-ever FDA marketing authorization of an AI diagnostic tool for sepsis. Sepsis, a complex and deadly condition, claims more lives than all cancers combined. https://lnkd.in/g-crKfn6 Join us in celebrating this historic “first" for healthcare innovation! #Sepsis #AI #FDAApproval #Prenosis

We are thrilled to announce that our Sepsis ImmunoScore™ has been recognized as one of TIME 's Best Inventions of 2024! We are honored to be featured among the world’s most transformative inventions. With thousands of submissions from across the globe, it’s an incredible achievement to stand out in such prestigious company. The Sepsis ImmunoScore™ is the first FDA-authorized AI diagnostic for sepsis, a groundbreaking achievement that marks a new era in precision diagnostics. This recognition is a testament to the incredible dedication of our Prenosis team, as well as the collaboration with our healthcare partners who continue to trust and believe in the power of innovation to save lives. Thank you to everyone who has been part of this journey. You can read the TIME article here: https://lnkd.in/gzj9erxz #TIMEBestInventions #SepsisImmunoScore #PrecisionDiagnostics #AIInHealthcare #SepsisAwareness #InnovationInHealthcare #Prenosis #HealthcareInnovation

Sepsis continues to be one of the leading causes of preventable deaths in healthcare, with up to 1.7 million cases each year in the U.S. alone, resulting in nearly 270,000 fatalities. The recent Agency for Healthcare Research and Quality (AHRQ) report on sepsis care shines a spotlight on these figures, encouraging us to come together to identify and treat sepsis earlier and more effectively. The report emphasizes the importance of early recognition and swift intervention, which can significantly improve patient outcomes and reduce mortality. https://lnkd.in/eXCDcqdG

In the recently published JAMA article, "FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine," three prominent FDA officials highlighted Prenosis and the Sepsis ImmunoScore™—the first-ever FDA-authorized AI diagnostic for sepsis—as a key example of successfully navigating the FDA’s regulatory process. JAMA, the most widely circulated general medical journal in the world, serves as an influential platform for discussing critical advancements in healthcare, further underscoring the significance of this recognition. As the FDA focuses on ensuring #AI tools are safe, effective and trustworthy, Prenosis is honored and excited to be recognized. Following the FDA framework not only guarantees safety and efficacy but also drives innovation. At Prenosis, we are proud to be at the forefront of this movement, striving to make precision medicine the standard of care for serious hospital conditions. Achieving FDA authorization for the Sepsis ImmunoScore™ through the De Novo pathway—an even more rigorous process than the 510(k) approval, which relies on existing predicate devices—demonstrates our commitment to regulatory excellence, safety, and innovation. This achievement continues to position the Sepsis ImmunoScore™ as a unique and groundbreaking AI-powered tool for sepsis. Read the article by FDA officials Haider J. Warraich, MD; Troy Tazbaz; and Robert M. Califf, MD: https://lnkd.in/giCD5fC5

Be sure you don't miss your opportunity to see the #Sepsis ImmunoScore, the first-ever AI Sepsis diagnostic, that is available on the #navify Algorithm Suite at #HLTH24 !

Robin Carver, RN, MSN, CIC

Let's Connect! I'm attending HLTH 2024, happening Oct 20 - 23 in Las Vegas. You can find me at Booth 1532 or you can message me directly. Come by and check out the #SepsisImmunoScore by Prenosis - the first FDA Authorized Sepsis #AI Diagnostic! #Sepsis #HLTHUSA #healthcareinnovation #healthcare #bebold

Join us on October 17 at the Arizona State University 's Annual National Diagnostics Summit panel, “The AI Revolution: Preparing for the Future,” featuring Prenosis ’ Carlos Lopez-Espina , Tempus AI ’s Ezra Cohen , ASU College of Health Solutions Hassan Ghasemzadeh , and Abbott Laboratories’ Brian Renley. The panel will be moderated by Arizona State University ’s Travis Schlappi . Carlos will discuss AI’s impact on healthcare and highlight the FDA authorization of the Sepsis ImmunoScore™, the first-ever FDA-authorized #AI diagnostic for #sepsis . To build the Sepsis ImmunoScore™, Prenosis leveraged its Immunix™ #AI platform and proprietary biobank/dataset, which includes more than 110,000 blood samples from over 27,000 patients. Immunix™ and the dataset—the world’s largest for acute care patients suspected of having serious infections—have the potential to be used to develop AI biomarkers beyond the Sepsis ImmunoScore™. Don’t miss this opportunity to learn about the future of AI in healthcare. Register here: https://lnkd.in/e9s2vPMr Event Details: 📅 Thursday, October 17, 2024 ⏰ 11:30 am to 12:15 pm 🌍 Location: Health Futures Center, 6161 East Mayo Blvd., Scottsdale, AZ

Bobby Reddy, Jr. , CEO of Prenosis , was named one of Crain's Chicago Business 40 Under 40! Under Bobby's guidance, Prenosis developed the Sepsis ImmunoScore—the first FDA-authorized AI diagnostic for sepsis—and is harnessing #AI algorithms to detect rapid immune responses and recommend personalized therapies. Earlier this week, we shared a link celebrating Bobby’s achievement alongside the other 39 honorees. Here’s the link to Crain's article highlighting Bobby's work (subscription required): https://lnkd.in/gjw7hP9X Another huge thank you to Crain’s for recognizing Bobby’s work, and for highlighting our mission at Prenosis to bring precision diagnostics and AI-driven insights to the forefront of patient care. #HealthcareLeadership #Crains40Under40 #AIInHealthcare #PrecisionDiagnostics #SepsisInnovation #PersonalizedMedicine #SepsisAwareness

We are incredibly proud to share that Prenosis CEO Bobby Reddy, Jr. has been recognized by Crain's Chicago Business as a 40 Under 40 honoree! This prestigious award highlights Bobby’s visionary leadership in advancing precision medicine. Thank you, Crain's Chicago Business , for acknowledging Bobby’s dedication and Prenosis' commitment to reshaping healthcare. We're excited to continue driving impactful change in patient care. #Leadership #HealthcareInnovation #AI #PrecisionMedicine #Sepsis #Diagnostics #40Under40 #CrainsChicago

Prenosis ’ Sepsis ImmunoScore™ has received FDA De Novo authorization—the first-ever FDA marketing authorization for an #AI diagnostic tool for #sepsis . This remarkable milestone was made possible through the unwavering dedication of our partners at LifeBridge Health , one of Maryland’s largest and most comprehensive health service providers. Their commitment to excellence in research and patient care has been instrumental in achieving this breakthrough. A special thank you to: Martin Gesheff , Paul Gurbel, Seanne Facho, Sarensa Palikhey , Rakesh Gupta , Udaya Tantry , Danielle Kraft, BSN, RN , Isabella Zafra , Rueshil Parekh, Parshotam Kundan, Rejina Niraula, Nathaniel Helwig, Dilip Baral, Damian Sidorski, and the entire LifeBridge Health team for your invaluable contributions. We look forward to continuing our partnership and making further strides in medical innovation. Together, we’re shaping the future! #HealthcareInnovation #MedicalAI #Sepsis #Prenosis

Metric
Company Name	Prenosis	AC Immune SA	Almac Group	Amgen Bangladesh
Symbol
MSH ID	COM:PRENOSIS	COM:ACIMMUNE	COM:ALMACGROUP	COM:AMGENBD
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Pharmaceuticals	Biotechnology
Country	US	CH	GB
Stage	Grant
Employee Count				10.00K
Website	prenosis.com	acimmune.com	almacgroup.com	amgenbd.com
LinkedIn	prenosis
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.15K
Web Traffic Growth	46.92
Valuation
Raised Capital	4.80M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

PREN

COM:PRENOSIS

Prenosis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue